1Departments of Renal Medicine and Biomedical Engineering, Centro di Ricerche Cliniche per le Malattie Rare “Aldo e Cele Daccò,” Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy
2Department of Management, Information and Production Engineering, University of Bergamo, Dalmine, Italy
3Unit of Radiology, Department of Imaging Diagnostics, Azienda Socio-Sanitaria Territoriale (ASST) Papa Giovanni XXIII, Bergamo, Italy
4Unit of Nephrology, Department of Medicine, Azienda Socio-Sanitaria Territoriale (ASST) Papa Giovanni XXIII, Bergamo, Italy
Correspondence: Prof. Giuseppe Remuzzi, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Via Stezzano 87, Bergamo 24126, Italy. Email: [email protected]
*TOOL Study Group: Coordinating Centre: Mario Negri Institute for Pharmacological Research IRCCS (MNI), Clinical Research Centre for Rare Diseases Aldo e Cele Daccò, Ranica (Bergamo); Research Coordinator: Giuseppe Remuzzi (Bergamo), Trial coordinator: Norberto Perico (Bergamo). Centre including patients: Clinical Research Centre for Rare Disease Aldo e Cele Daccò, Ranica (Piero Ruggenenti Principal Investigator, Norberto Perico, Matias Trillini, Erica Daina, Elena Bresin, Diego Curtò, Giulia Gherardi, Daniela Cugini, Silvia Prandini, Veruska Lecchi, Diana Cadè, Sara Gamba, Angelo Diffideni, Chiara Guarinoni). Centre for screening only: ASST Papa Giovanni XXIII Nephrology Unit (Alessia Gennarini, Maria Rosa Caruso, Valentina Leone, Stefano Rota), Centralised activities: Monitoring, Drug Distribution and Pharmacovigilance (Nadia Rubis, Wally Calini, Davide Villa, Olimpia Diadei at MNI); Database and Data Validation (Davide Martinetti, Sergio Carminati at MNI); Randomisation (Giovanni Antonio Giuliano at MNI); Data Analysis (Annalisa Perna, Francesco Peraro, Tobia Peracchi at MNI); Medical Imaging (Anna Caroli, Giulia Villa, Andrea Remuzzi at MNI and Paolo Brambilla, Francesca Abbadini, Sandro Sironi at ASST Papa Giovanni XXIII Radiology Unit); Laboratory Measurements (Daniela Cugini, Flavio Gaspari, Fabiola Carrara, Silvia Ferrari, Nadia Stucchi, Antonio Nicola Cannata at MNI); Regulatory Affairs (Paola Boccardo, Sara Peracchi, Jennifer Piffari at MNI); and IMP management (Francesco Gregis, Simone Borchetto, Bianca Taddei, Erika Diani at ASST Papa Giovanni XXIII Pharmacy).
See related editorial, “Concurrent Targeting of Vasopressin Receptor 2 and Somatostatin Receptors in Autosomal Dominant Polycystic Kidney Disease: A Promising Approach for Autosomal Dominant Polycystic Kidney Disease Treatment?” on pages 154–156.
